CTOs on the Move

Dyne Therapeutics

www.dyne-tx.com

 
Dyne was founded with a singular focus: to transform the lives of people with serious muscle diseases by pioneering muscle-targeted therapies. Our proprietary technologies provide the foundation for breakthrough treatments. We have assembled a world-class team of experts who are united by their commitment to fulfill this mission.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.dyne-tx.com
  • 830 Winter Street
    Waltham, MA USA 02451
  • Phone: 781.786.8230

Executives

Name Title Contact Details

Funding

Dyne Therapeutics raised $50M on 04/03/2019
Dyne Therapeutics raised $115M on 08/10/2020
Dyne Therapeutics raised $168M on 01/21/2021

Similar Companies

CM-Tec Inc

CM-Tec Inc is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dova Pharmaceuticals

Dova is a clinical-stage pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet medical need. With a nimble approach and a team of bright minds aglow with passion, we’re...

GPB Scientific

GPB Scientific is transforming the process of purifying and enriching cells for cell therapy production. Reliable cell recovery and expansion are fundamental to the successful scale up of CAR-T or any therapeutic cell manufacturing process. GPB has developed a high-throughput, automatable, microfluidic closed-system for leukapheresis sample preparation and downstream processing of cells for CAR-T and other cell therapy production. This breakthrough reduces cell losses and skill-intensive manual steps.

aTyr Pharma

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.

Roka Bioscience

Roka Bioscience is a Warren, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.